Literature DB >> 16940534

Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Wenyu Lin1, Sun Suk Kim, Elaine Yeung, Yoshitaka Kamegaya, Jason T Blackard, Kyung Ah Kim, Michael J Holtzman, Raymond T Chung.   

Abstract

Emerging data have indicated that hepatitis C virus (HCV) subverts the host antiviral response to ensure its persistence. We previously demonstrated that HCV protein expression suppresses type I interferon (IFN) signaling by leading to the reduction of phosphorylated STAT1 (P-STAT1). We also demonstrated that HCV core protein directly bound to STAT1. However, the detailed mechanisms by which HCV core protein impacts IFN signaling components have not been fully clarified. In this report, we show that the STAT1 interaction domain resides in the N-terminal portion of HCV core (amino acids [aa] 1 to 23). This domain is also required to produce P-STAT1 reduction and inhibit IFN signaling transduction. Conversely, the C-terminal region of STAT1, specifically the SH2 domain (aa 577 to 684), is required for the interaction of HCV core with STAT1. The STAT1 SH2 domain is critical for STAT1 hetero- or homodimerization. We propose a model by which the binding of HCV core to STAT1 results in decreased P-STAT, blocked STAT1 heterodimerization to STAT2, and, therefore, reduced IFN-stimulated gene factor-3 binding to DNA and disrupted IFN-stimulated gene transcription.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940534      PMCID: PMC1563912          DOI: 10.1128/JVI.00459-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  A reinterpretation of the dimerization interface of the N-terminal domains of STATs.

Authors:  Xiaomin Chen; Rashna Bhandari; Uwe Vinkemeier; Focco Van Den Akker; James E Darnell; John Kuriyan
Journal:  Protein Sci       Date:  2003-02       Impact factor: 6.725

2.  C-terminal region of STAT-1alpha is not necessary for its ubiquitination and degradation caused by mumps virus V protein.

Authors:  Noriko Yokosawa; Shin-Ichi Yokota; Toru Kubota; Nobuhiro Fujii
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice.

Authors:  Alex Blindenbacher; Francois H T Duong; Lukas Hunziker; Simone T D Stutvoet; Xueya Wang; Luigi Terracciano; Darius Moradpour; Hubert E Blum; Tonino Alonzi; Marco Tripodi; Nicola La Monica; Markus H Heim
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

Review 4.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

5.  Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.

Authors:  Valérie Castet; Chantal Fournier; Alexandre Soulier; Rozenn Brillet; Joliette Coste; Dominique Larrey; Daniel Dhumeaux; Patrick Maurel; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3.

Authors:  Johannes G Bode; Stephan Ludwig; Christina Ehrhardt; Ute Albrecht; Andreas Erhardt; Fred Schaper; Peter C Heinrich; Dieter Häussinger
Journal:  FASEB J       Date:  2003-01-22       Impact factor: 5.191

7.  Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.

Authors:  Jay H Hoofnagle; Marc G Ghany; David E Kleiner; Edward Doo; Theo Heller; Kittichai Promrat; Janus Ong; Farooq Khokhar; Alejandro Soza; David Herion; Yoon Park; James E Everhart; T Jake Liang
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

8.  Expression and identification of hepatitis C virus polyprotein cleavage products.

Authors:  A Grakoui; C Wychowski; C Lin; S M Feinstone; C M Rice
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Amino acids 1-20 of the hepatitis C virus (HCV) core protein specifically inhibit HCV IRES-dependent translation in HepG2 cells, and inhibit both HCV IRES- and cap-dependent translation in HuH7 and CV-1 cells.

Authors:  Dongsheng Li; Seyed Taghi Takyar; William B Lott; Eric J Gowans
Journal:  J Gen Virol       Date:  2003-04       Impact factor: 3.891

10.  Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Authors:  Robert E Lanford; Bernadette Guerra; Helen Lee; Devron R Averett; Brad Pfeiffer; Deborah Chavez; Lena Notvall; Catherine Bigger
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  82 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner.

Authors:  Wenyu Lin; Wei-Lun Tsai; Run-Xuan Shao; Guoyang Wu; Lee F Peng; Lydia L Barlow; Woo Jin Chung; Leiliang Zhang; Hong Zhao; Jae-Young Jang; Raymond T Chung
Journal:  Gastroenterology       Date:  2010-03-12       Impact factor: 22.682

3.  EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Authors:  Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91.

Authors:  Yusuke Funaoka; Naoya Sakamoto; Goki Suda; Yasuhiro Itsui; Mina Nakagawa; Sei Kakinuma; Takako Watanabe; Kako Mishima; Mayumi Ueyama; Izumi Onozuka; Sayuri Nitta; Akiko Kitazume; Kei Kiyohashi; Miyako Murakawa; Seishin Azuma; Kiichiro Tsuchiya; Mamoru Watanabe
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

5.  Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.

Authors:  Raymond T Chung; Michael Gale; Stephen J Polyak; Stanley M Lemon; T Jake Liang; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 6.  Treatment failure in hepatitis C: mechanisms of non-response.

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Hepatol       Date:  2008-12-03       Impact factor: 25.083

7.  Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.

Authors:  Feyza Gunduz; Chaithanya Mallikarjun; Luis A Balart; Srikanta Dash
Journal:  Exp Mol Pathol       Date:  2013-11-08       Impact factor: 3.362

8.  The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.

Authors:  Wenyu Lin; Chuanlong Zhu; Jian Hong; Lei Zhao; Nikolaus Jilg; Dahlene N Fusco; Esperance A Schaefer; Cynthia Brisac; Xiao Liu; Lee F Peng; Qikai Xu; Raymond T Chung
Journal:  J Hepatol       Date:  2014-12-03       Impact factor: 25.083

Review 9.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

10.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.